Table 3.
| A PIP questionnaire criterion-oriented validity based on patient subgroups | ||||
|---|---|---|---|---|
| Item | Total | QoL | SF | PW |
| Priapism Activity†, median (IQR) | ||||
| Active (n=42) | 45.5 (30.8–57.3) | 18.5 (12.8–21.0) | 15.5 (9.0–21.3) | 13.0 (8.8–16.0) |
| Remission (n=8) | 21.5 (16.5–42.3) | 10.0 (8.0–14.8) | 7.5 (5.3–17.3) | 4.0 (3.0–8.8) |
| P Value | 0.0106 | 0.0159 | 0.0921 | 0.0017 |
| Priapism Severity†, median (IQR) | ||||
| High (n=16) | 55.5 (40.5–67.0) | 20.5 (18.3–23.8) | 20.5 (11.3–26.3) | 15.0 (11.8–18.0) |
| Low (n=34) | 35.0 (24.5–48.3) | 14 (4.0–19.3) | 10.0 (6.0–19.3) | 9.0 (4.8–13.0) |
| P Value | 0.0019 | 0.0020 | 0.0244 | 0.0007 |
| Erectile Dysfunction‡, median (IQR) | ||||
| Present (n=16) | 53.0 (32.8–63.3) | 19.5 (12.0–24.0) | 21.5 (13.0–27.0) | 11.5 (7.3–18.8) |
| Absent (n=32) | 36.0 (24.3–51.8) | 16.5 (10.3–20.0) | 10.5 (6.3–19.5) | 9.5 (6.3–14.8) |
| P Value | 0.0250 | 0.1366 | 0.0024 | 0.2498 |
| Priapism Etiology, median (IQR) | ||||
| SCD (n=36) | 38.5 (25.3–52.3) | 16.0 (10.3–19.8) | 12.0 (7.0–19.8) | 10.0 (6.3–14.0) |
| Non-SCD (n=18) | 52.0 (36.5–68.5) | 20 (15.3–24.3) | 20.0 (10.3–24.8) | 12.0 (8.0–16.5) |
| P Value | 0.0318 | 0.0170 | 0.0432 | 0.1596 |
| B Correlation coefficients for a priori hypotheses | ||||||||
|---|---|---|---|---|---|---|---|---|
| Item | Total | P Value | QoL | P Value | SF | P Value | PW | P Value |
| Priapism Activity† (Active vs Remission) |
0.367 | 0.009 | 0.346 | 0.014 | 0.243 | 0.090 | 0.451 | 0.001 |
| Priapism Severity† (High vs Low) |
0.446 | 0.001 | 0.443 | 0.001 | 0.323 | 0.022 | 0.487 | 0.0003 |
| Erectile Dysfunction‡ (Present vs Absent) |
0.329 | 0.023 | 0.219 | 0.135 | 0.444 | 0.002 | 0.170 | 0.249 |
PIP = priapism impact profile, QoL = quality of life, SF = sexual function, PW = physical wellness SCD = sickle cell disease, yrs = years, IQR = Interquartile Range,
†
values absent for 4 patients,
‡
values absent for 6 patients